– Reuters
Alliance Global Partners Reiterates Buy on Tonix Pharmaceuticals, Maintains $6.5 Price Target
Alliance Global Partners analyst James Molloy reiterates Tonix Pharmaceuticals (NASDAQ:TNXP) with a Buy and maintains $6.5 price target.